Amgen has filed suit against Swiss drug major Roche for infringing its patents on erythropoietin, the red blood cell growth factor that represents a $5 billion dollar franchise for the world's largest biotechnology company.
The catalyst for the lawsuit is Roche's decision to develop a long-acting EPO product, called CERA (R744), which will be a direct competitor to Amgen's own Aranesp (darbepoetin alfa) and Epogen (epoetin alfa). CERA is in Phase III trials for renal anaemia and is scheduled for regulatory submission in 2006.
Stand back. This is going to be bloody.
PS
http://pharmagossip.blogspot.com/2005/10/bundle-up-its-getting-chilly.html
Remember, J&J are suing Amgen for alleged bundling deals.
Source: PharmaTimes
No comments:
Post a Comment